Further, the data from two different clinical trials showed that NER, in combination with either capecitabine or T-DM1, was effective against brain metastatic ERBB2+ BC, with grade 3 and 4 levels of toxicity, respectively [14,15]. The gene discussed is ERBB2; the disease is breast cancer.